LYMPHOMA, LARGE B-CELL, DIFFUSE
Clinical trials for LYMPHOMA, LARGE B-CELL, DIFFUSE explained in plain language.
Never miss a new study
Get alerted when new LYMPHOMA, LARGE B-CELL, DIFFUSE trials appear
Sign up with your email to follow new studies for LYMPHOMA, LARGE B-CELL, DIFFUSE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New immunotherapy MK-1045 shows promise for tough lymphomas
Disease control Recruiting nowThis study tests a new immunotherapy drug, MK-1045, in about 200 people with two types of non-Hodgkin lymphoma (follicular lymphoma and diffuse large B-cell lymphoma) that have not responded to at least two prior treatments. The main goals are to check safety and see if the cance…
Matched conditions: LYMPHOMA, LARGE B-CELL, DIFFUSE
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 26, 2026 04:43 UTC
-
New Dual-Targeting CAR-T therapy shows promise for tough lymphoma
Disease control Recruiting nowThis study tests a new treatment called JNJ-90014496 (prizlo-cel) for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, modified to target two markers on cancer cells (CD19 and CD20). Th…
Matched conditions: LYMPHOMA, LARGE B-CELL, DIFFUSE
Phase: PHASE1, PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 26, 2026 04:32 UTC
-
New hope for aggressive lymphoma: triple therapy shows promise
Disease control Recruiting nowThis study tests whether adding two targeted drugs (glofitamab and polatuzumab) to standard chemotherapy (R-CHP) can improve outcomes for people with high-risk diffuse large B-cell lymphoma. About 41 adults who have not been treated before will receive the combination. The main g…
Matched conditions: LYMPHOMA, LARGE B-CELL, DIFFUSE
Phase: PHASE2 • Sponsor: Jennifer Crombie, MD • Aim: Disease control
Last updated May 26, 2026 04:31 UTC
-
New hope for blood cancer: experimental drug combo aims to beat current standard
Disease control Recruiting nowThis study tests whether a new drug (zilovertamab vedotin) combined with standard chemotherapy works better than another approved drug combo for people with a specific type of fast-growing blood cancer called GCB DLBCL. About 594 adults who have not been treated before will recei…
Matched conditions: LYMPHOMA, LARGE B-CELL, DIFFUSE
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 26, 2026 04:29 UTC
-
Second chance: lymphoma patients get access to imperfect but potentially lifesaving CAR T-Cell therapy
Disease control AVAILABLEThis program gives people with large B-cell lymphoma access to a CAR T-cell therapy called lisocabtagene maraleucel (liso-cel) when their specific batch didn't pass all quality checks. Participants receive chemotherapy before the treatment. The goal is to offer a potential benefi…
Matched conditions: LYMPHOMA, LARGE B-CELL, DIFFUSE
Sponsor: Juno Therapeutics, a Subsidiary of Celgene • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
Smart PET scan targets hidden cancers with precision
Diagnosis Recruiting nowThis study tests a new type of PET/CT scan that looks for a protein called CD70 on cancer cells. It aims to better detect kidney cancer, lymphoma, and nasopharyngeal cancer in 300 adults. The scan may help doctors see tumors more clearly and guide treatment decisions.
Matched conditions: LYMPHOMA, LARGE B-CELL, DIFFUSE
Phase: PHASE2 • Sponsor: RenJi Hospital • Aim: Diagnosis
Last updated May 22, 2026 13:53 UTC